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EKSPRESI PENANDA APOPTOSIS PADA SALURAN DARAH MIKRO 
PESAKIT DIABETES MELLITUS JENIS 2 DI HOSPITAL UNIVERSITI SAINS 
MALAYSIA 
 
ABSTRAK 
 
Perubahan salur darah pada pesakit diabetes jenis 2 berkait rapat 
dengan kesan jangka panjang komplikasi diabetes. Sehubungan dengan itu, 
kajian ini bertujuan untuk mengkaji hubungan antara parameter histologi 
seperti penanda apoptotsis, Bax (penanda pro-apoptotsis), Bcl-2 (penanda 
anti-apoptotsis) dan perubahan morfologi salur darah menggunakan teknik 
immunohistokimia (IHC), haematoxylin dan eosin (H&E) dan pewarnaan khas 
bagi perubahan salur darah yang terdiri daripada ketebalan sel endotelium 
(ECT), pengiraan sel endotelium (ECC) dan pengiraan salur darah (BVC) 
dengan parameter biokimia kawalan diabetes untuk membolehkan parameter 
histopatologi digunakan sebagai prediktor vaskulopati. Kajian hirisan lintang ini 
bermula dari Ogos 2003 hingga November 2005. Subjek kajian terdiri daripada 
41 orang pesakit diabetes jenis 2 dan 36 orang bukan pesakit diabetes 
(kontrol), berumur antara 20 hingga 70 tahun dari Hospital Universiti Sains 
Malaysia. Biopsi kulit dan sampel darah diambil daripada setiap pesakit 
diabetes dan kontrol. Tisu biopsi kulit diwarnakan dengan pewarnaan 
histokimia untuk mengkaji ekpresi Bax dan Bcl-2 yang dilakukan di makmal 
Patologi, Pusat Pengajian Sains Perubatan (PPSP), USM. Ujian darah yang 
dibuat adalah glukosa plasma semasa berpuasa (FPG), trigliserida (TG), 
kolesterol total (TC), kolesterol lipoprotein ketumpatan tinggi (HDL-c) dan 
kolesterol lipoprotein ketumpatan rendah (LDL-c) yang telah dilakukan di 
makmal Patologi Kimia, PPSP, USM. Manakala ujian darah hemoglobin A1c 
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terglikosil (HbA1c) telah dilakukan di makmal Endokrin, PPSP, USM. Didapati 
bahawa taburan ekspresi Bax meningkat dengan signifikan  (p<0.05) apabila 
dibandingkan di antara pesakit diabetes dan kontrol. Manakala ekspresi Bcl-2 
didapati meningkat di kalangan pesakit kontrol dengan sangat signifikan 
(p<0.001) apabila dibandingkan dengan pesakit diabetes. Didapati bahawa min 
ECT, ECC dan BVC pula menunjukkan perbezaan yang signifikan (p<0.05) di 
kalangan  pesakit diabetes dan kontrol yang menunjukkan ekspresi Bax dan 
Bcl-2 positif atau negatif. Seterusnya, min FPG menunjukkan perbezaan yang 
signifikan dengan ekspresi Bax positif dan negatif. Walaubagaimanapun, tidak 
ada perbezaan nyata di antara bacaan A1C, TG, TC, HDL-c dan LDL-c dengan 
ekspresi Bax. Menariknya, FPG dan HbA1c menunjukkan perbezaan signifikan 
yang tinggi (p<0.001) dengan ekspresi Bcl-2. FPG dan HbA1c juga 
menunjukkan perbezaan signifikan yang tinggi (p<0.001) di antara pesakit 
diabetes dan kontrol. Perubahan salur darah menunjukkan perbezaan min 
ECT, ECC dan BVC yang amat signifikan di antara pesakit diabetes dan 
kontrol, tetapi tidak ada perbezaan nyata bagi TG, TC dan LDL-c. 
Kesimpulannya, kajian ini telah mendapati bahawa ahli famili Bcl-2 seperti Bax 
dan Bcl-2 memainkan peranan penting dalam penghasilan salur darah yang 
baru tetapi tidak normal. Penemuan baru adalah ECT, ECC dan BVC 
memainkan peranan dalam mengenalpasti perubahan salur darah yang tidak 
normal. Perubahan salur darah juga berkait dengan kandungan biokimia darah 
pesakit diabetes seperti FPG dan HbA1c, manakala kandungan lipid profilnya 
tidak konsisten. 
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EXPRESSION OF APOPTOSIS MARKERS IN THE SKIN 
MICROVASCULATURE OF PATIENTS WITH DIABETES MELLITUS TYPE 2 
AT HOSPITAL UNIVERSITI SAINS MALAYSIA 
 
ABSTRACT 
The microvascular changes in diabetes are directly related to the long 
term complications of diabetes. Therefore, this research is proposed to study 
the relationship between the histopathological parameters such as apoptotic 
markers namely Bax (pro-apoptotic marker) and Bcl-2 (anti-apoptotic maker) 
and morphology of microvasculature which are endothelial cell thickness 
(ECT), endothelial cell counting (ECC) and blood vessel counting (BVC) using 
immunohistochemistry (IHC), haematoxylin & eosin (H&E) and special stain of 
vasculopathy with biochemical parameters of diabetes control, in order to use 
the histopathology parameters as predictors of diabetes vasculopathy. A cross-
sectional study was conducted from August 2003 to November 2005. Forty one 
type 2 diabetes patients and 36 non diabetes (control) patients (20 to 70 years 
old) from Hospital Universiti Sains Malaysia (HUSM) were included in this 
study. Skin biopsy and blood samples were taken from each diabetes and 
control patients. The skin biopsy tissue samples were stained with 
immunohistochemistry stain for Bax and Bcl-2 expression in the Pathology 
laboratory, School of Medical Sciences, USM. Blood samples were collected 
for fasting plasma glucose (FPG), triglycerides (TG), total cholesterol (TC), high 
density lipoprotein cholesterol (HDL-c) and low density lipoprotein cholesterol 
(LDL-c) analyses in the Chemical Pathology laboratory. The glycosylated 
hemoglobin A1c (HbA1c) was analysed in the Endocrine laboratory. Bax 
expression was significantly increased in diabetes patients (p<0.05). However, 
Bcl-2 expression was significantly increased (p<0.001) in control patients when 
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compared with diabetes patients. There were significant differences (p<0.05) of 
mean ECT, ECC and BVC between diabetic and control patients with positive 
or negative Bax and Bcl-2 expressions. FPG showed significant difference of 
mean (p<0.05) with expression of positive and negative Bax. However, there 
were no significant differences for HbA1c, TG, TC, HDL-c and LDL-c with Bax 
expression. Interestingly, FPG and A1C showed highly significant differences 
(p<0.001) with Bcl-2 expression.  Between diabetic and control patients, there 
was a significant mean difference (p<0.001) for FPG and HbA1c, but there 
were no significant differences for TG, TC, and LDL-c. The mean difference of 
microvasculature was significant (p<0.05) for ECT, ECC and BVC between 
diabetes and control patients. From this study we found that the expression of 
Bcl-2 family such as Bax and Bcl-2, play an important role in contributing to 
abnormal blood vessel proliferation in diabetic patients. A new finding is that 
ECT, ECC and BVC are indicative of blood vessel abnormality in diabetic 
patients. These microvasculatures in diabetes patients were also associated 
with biochemical changes such as in FPG and HbA1c, while the lipid profile 
fraction associations were inconsistent. 
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CHAPTER 1 
INTRODUCTION 
 
1.1 Type 2 Diabetes 
Type 2 Diabetes is a common chronic disorder and represents a serious 
disease in the world nowadays. DM referred to as diabetes, is characterized by 
the presence of an excess of glucose in the blood and tissues of the body. 
Diabetes in Greek means siphon, referring to the release of excess urine, and 
mellitus is honey in Latin, implying the presence of glucose in urine. Thus, 
diabetes mellitus means the passage of large amount of glucose enriched 
urine. There are a number of different types of DM. All of these have different 
aetiologies and course of treatment but subjects with diabetes have a common 
problem, whereby the body has little or no ability to absorb glucose from the 
bloodstream into cells. Subsequently, the cells cannot get hold of their primary 
fuel source, glucose and the blood glucose level rises. Usually the blood 
glucose level is controlled by the hormone called insulin. It helps cells to absorb 
glucose from the bloodstream and use it for energy production. Consequently, 
the failures of production or the action of insulin cause diabetes.  
 
The prevalence of DM is on the increasing and an estimated 239 million 
people worldwide are expected to develop DM by the year 2020. Data shows 
that in 1995, about 1,380,000 adults had confirmed DM, and it is has been 
estimated that about 1,000,000 more people have diabetes which has not been 
diagnosed (www.diabetes.org.uk, 2002). Diabetes prevalence increases with 
age, where in United Kingdom, one in twenty people over the age of 65 years 
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have type 2 diabetes and this increases to one in five people over the age of 85 
years (www.doh.gov.uk/nsf/diabetes, 2002).  
 
The factors influencing the increase in type 2 diabetes are varied and as 
yet have not been fully understood. Nevertheless, these factors are expected to 
consist of an increase in the number of people at risk of developing type 2 
diabetes due to refusal of physical activity, increasing dietary energy intake, 
survival of people with type 2 diabetes and recognition of previously 
undiagnosed type 2 diabetes. Early detection of type 2 diabetes is a crucial 
factor in preventing the development of diabetic complications. There are now 
some good evidence that changes in lifestyle may help to delay and possibly 
prevent the onset of type 2 diabetes. 
 
After taking so long to gain recognition, the awareness in diabetes is 
now rising speedily (Zimmet, 1999) and it is a stimulating time for researchers 
and clinicians to be involved in the study and treatment of the disease. 
According to the report from Mafauzy et al. (1999) the prevalence of DM and 
impaired glucose intolerance (IGT) were 10.5 % and 16.5 % respectively in 
Kelantan, a north-east state of Malaysia (Mafauzy et al., 1999). Meanwhile 0.3 
% and 4.4 % were Orang Asli and 4.7 % and 11.3 % were Malays (Ali et al., 
1993; Choi & Shi, 2001).  
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Type 2 diabetes is more prevalent in the general population and the 
increasing prevalence (8%-45%) of type 2 diabetes in children and adolescents 
may be reversed within one to two decades (Fagot-Campagna et al., 2000; 
Fagot-Campagna & Narayan, 2001).  
 
1.2 Distribution of Type 2 Diabetes  
The worldwide prevalence of diabetes (>90% of cases of diabetes) is 
subject to increase from the present estimate of 150 million to 220 million in 
2010, and 300 million (5.4% of the world population) in 2025 (Amos et al., 
1997; King et al., 1998). The prevalence of type 2 diabetes in America is the 
highest among Pima Indians, followed by Hispanics, Blacks and Whites (Ismail 
& Gill, 1999). The diabetes epidemic around the world has been most marked 
in non-European populations, as evidenced by studies from Native American 
and Canadian communities, Pacific and Indian Ocean island populations (de 
Courten et al., 1997), groups in India (Ramachandran et al., 1997) and 
Australian Aboriginal communities (O’Dea, 1991). In the Pacific island of Nauru, 
where diabetes was almost unknown 50 years ago, it is now present in 
approximately 40% of adults (Zimmet et al., 1990).  
 
The potential for increase in the number of cases of diabetes is greatest 
in Asia (Amos et al., 1997). Data from Mauritius demonstrated the highest yet 
reported prevalence in people of Chinese pulling out, in addition to 
demonstrating a high diabetes prevalence and a distinguished worldly increase 
between 1987 and 1998 in Asian Indians and Creoles (Zimmet, 1999). 
Together with evidence of prevalence of type 2 diabetes which has doubled 
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between 1984 and 1992 in Singaporean Chinese (Tan et al., 1999), and the 
high prevalence in Taiwan (Chou et al., 1992), these data provide alarming 
indicators of the size in future epidemic in the People’s Republic of China. 
Here, the overall prevalence of type 2 diabetes was, until recently, less than 
1%. Recent studies showed a threefold increase in prevalence in certain areas 
of China within the past two decades (Pan et al., 1997).  
 
The Third National Health and Nutrition Examination Survey (NHANES 
III), 1988-1994 data show that diabetes (diagnosed and undiagnosed 
combined) affects 7.8% of adults aged 20 years and above. In the U.S., the 
rate is 18.8% for adults aged 60 years and above (Harris et al., 1998).  
 
The high prevalence of undiagnosed diabetes and the proportion of 
cases with evidence of complications at diagnosis undoubtedly create a very 
important need for screening. Between 35-50% of diabetes cases are 
undiagnosed at any one time. 
 
Most cases will be of type 2 diabetes, which is strongly associated with a 
sedentary lifestyle and obesity (Zimmet, 1999). This trend of increasing 
prevalence of diabetes and obesity has already imposed a huge burden on 
healthcare systems and this will continue to increase in the future (Zimmet, 
2000; ADA, 1998). 
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The new prevalence of diabetes cases were 0.2% (0% to 1.4%) and 
2.8% (1.6% - 4.7%) in patients whose individual risk factor was age over 45 
and in patients aged over 45 with one or more additional risk factors for 
diabetes, respectively (Lawrence et al., 2001). The higher diabetes prevalence 
was associated with ethnic group, age (≥ 40 years), dietary intake, obesity and 
lack of physical activity.   
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1.3 Diagnosis of Type 2 Diabetes 
 Diagnosis of type 2 diabetes depends on the measurement of glucose 
levels in the blood. Oral glucose tolerance testing (OGTT) was introduced when 
the measurement of blood glucose was much less accurate than it is today. It 
involves measuring the rise and subsequent fall of blood glucose values after 
drinking 75 g of anhydrous glucose from the start to 2 hours after drinking (the 
defining glucose values vary according to which type of sample is used). The 
test is often performed with an overnight fasting and the 2 hours values which 
are generally the most informative. Indeed, with specific blood glucose 
measurement the fasting value alone is very rational of glucose tolerance.  
 
 When the symptoms are clear cut, random or fasting glucose levels will 
be remarkably raised and diagnostic. The correct defining levels are a matter of 
opinion and vary from time to time. It is most useful to refer to the 
recommendations from the current World Health Organization (WHO, 1999) 
(Table 1.1). The differences between plasma and whole-blood glucose 
concentrations and between capillary and venous level, are too frequently 
unnoticed. Whole-blood values are about 10 to 15 percent lower than those of 
plasma and capillary values are 7 percent higher than venous values in the 
fasting state and 8 percent higher after a glucose load. These differences are 
important because clinical laboratories may use venous plasma whereas 
bedside monitoring techniques use capillary whole blood or plasma. 
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Table 1.1 Level of glucose for fasting period and after 2 hours taking glucose 
for DM diagnostic and for hyperglycemia categories 
 
 
Categories 
 
Intake Time
Concentration of Glucose, mmol/L (mg/dl) 
Whole blood Plasma 
Venous Capillary Venous Capillary 
 
 
Diabetes 
mellitus 
 
Fasting 
≥ 6.1 
(110) 
≥ 6.1 
(110) 
≥ 7 
(126) 
≥ 7 
(126) 
2 hours 
after taking 
glucose* 
≥ 10 
(180) 
≥ 6.1 
(200) 
≥ 11.1 
(200) 
≥ 12.2 
(220) 
 
Impaired 
Glucose 
Tolerance 
(IGT) 
 
Fasting 
< 6.1 
(110) 
< 6.1 
(110) 
< 7 
(126) 
< 7 
(126) 
2 hours 
after taking 
glucose* 
≥ 6.7- < 10 
(120-180) 
 
≥7.8 -
<11.1 
(140-200) 
 
≥7.8 -<11.1 
(140-200) 
 
≥8.9-<12.2 
(160-220) 
 
 
Impaired 
Fasting 
Glucose 
(IFG) 
 
Fasting 
≥ 5.6-<6.1 
(100-110) 
≥ 5.6-<6.1 
(100-110) 
 
≥ 6.1-<7 
(110-126) 
 
≥ 6.1-<7 
(110-126) 
 
2 hours 
after  
glucose 
load* 
< 6.7 
(120) 
< 7.8 
(140) 
< 7.8 
(140) 
< 8.9 
(160) 
 
Source: Consultant report WHO (1999). 
*75 g oral glucose load 
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1.4 Complications of Type 2 Diabetes  
 Diabetic complications are more frequent in type 2 diabetes patients with 
about 50% suffering from one or more complications at the time of diagnosis. 
The complications of diabetes, often called late complications are damage and 
loss of function in organs that have glucose transporters which are not sensitive 
to insulin and thus do not require insulin for glucose entry (Vinik et al., 2003). 
Diabetic complications are divided into microvascular and macrovascular 
complications. Microvascular complications include damages to the retina of 
the eye leading to loss of vision (Bosco et al., 2005), the nephrons of the kidney 
leading to chronic renal failure and the blood supply of cells of the peripheral 
nervous system with loss of nerve function. Whereas in macrovascular 
complications there are disorders of lipid metabolism and blood coagulation 
leading to narrowing of vessels and altered blood flow in the cardiovascular 
system resulting in heart attack, stroke and limb amputation (Cameron et al., 
2001). Dyslipidaemia, hypertension, obesity, smoking and lack of exercise are 
the other factors contributing to the risk of diabetic complications (Mwendwa et 
al., 2005). 
  
 Development of diabetic complications in type 2 diabetes begins with 
repeated acute, but reversible, changes in cellular metabolism caused by 
increased levels of glucose. Alterations in target tissue function and structure 
follow and progress to the clinically recognised conditions referred to above as 
microvascular complications. Atherosclerosis is a result of macrovascular 
complications. Both microvascular and macrovascular disease can affect the 
coronary artery and cause cardiac dysfunction. Furthermore, in epidemiological 
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studies, the microvascular and macrovascular complications are linked. The 
morbidity risk associated with all types of diabetes mellitus is listed in Table 
1.2. 
 
Table 1.2 List of risks mobility complications in all types of DM 
 
Complications Relative risk* 
Amputation 40 
End-stage renal disease (ESRD) 25 
Blind 20 
Myocardial infarction (MI) 2-5 
Stroke 2-3 
 
*Compared with non-diabetes patients (Donnelly et al., 2000) 
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1.4.1 Microvasculature 
 Most of the long-term complications of diabetes mellitus stalk from 
failure of the microvasculature. It has long been documented that microvascular 
disease underlies diabetic retinopathy as well as nephropathy and diabetic foot 
(Wild et al., 2004). Recently, damage to the microvasculature has been a 
concern in diabetic cardiopathy (Poornima et al., 2006) as well as the 
pathogenesis of diabetic neuropathy (Kim and Robinson, 2006). 
Microangiopathy is not a singular process but involves different stages of 
development. In the development of diabetes, changes of microcirculation 
function are marked which may be reversible if the metabolic abnormality is 
normalised. Progressive increasing duration of diabetes causes structural 
adaptive changes to occur, most obvious of which is basement membrane 
thickening, owing to buildup of extravascular matrix proteins (fibronectin). The 
thickening of the basement membrane is a novel discovery and have been 
demonstrated in the microvasculature of the eye (Fong et al., 2004), kidney 
(ADA, 1998), muscle (Klein et al., 1987), and skin (Yasuda et al., 1990).  
 
The importance of structural adaptive changes of the underlying 
microvasculature that affect its functions has been discussed. It is adequately 
prevalent after prolonged duration of diabetes and is regarded as the 
ultrastructural hallmark of diabetes mellitus. Eventually, in many microvascular 
networks, complete failure of transfer function occurs possibly precipitated by 
microvascular occlusion. Such terminal event outcome is most well accepted in 
areas of underperfusion such as the retinal microcirculation. These areas of 
poor tissue nutrition may activate reparative mechanisms which in the case of 
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retinopathy may be damaging in themselves as the new vessels may develop 
into the vitreous of the eye and subjected to the risk of bleeding and hence 
obscuring the light path to the retina.  
 
Although it is usual to believe that the microangiopathic complications 
occur frequently in type 2 diabetes, current clinical observation reveals that 
maculopathy is the major problem faced by those with type 2 diabetes (Jaap & 
Tooke, 1995). Nephropathy tends to run a slower course in type 2 diabetes.  
 
Furthermore, it is well known that the prevalence of hypertension (in the 
absence of nephropathy) is much greater in type 2 diabetes, as is the overall 
risk of arterial disease, possibly reflecting the expression of the insulin 
resistance syndrome, of which type 2 diabetes is simply part of. As it becomes 
clearer that type 2 diabetes is a heterogeneous collection of conditions 
resulting from various degrees of insulin-resistance and β-cell failure, it may not 
be sufficient to fully understand the nature of diabetic microangiopathy. 
 
The microvascular changes in diabetes are associated with endothelial 
dysfunction. Moreover, vascular endothelial cells form the inner lining of all 
blood vessels. During both normal and pathological development, the formation 
of new vessels and the regression of preexisting ones are dependent on the 
balance between endothelial cell proliferation and endothelial cell apoptosis. In 
mature vessels, endothelial cell turnover is also under the control of these 
tightly regulated phenomena. Since the vascular endothelium is involved in 
various physiological processes, endothelial cell apoptosis may represent an 
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initial step in a variety of pathological situations such as atherosclerosis and 
hypertension. As for other cell types, it has been hypothesized that interactions 
of endothelial cells with their microenvironment may be critical for their survival 
(Mallat & Tedgui, 2000).  
 
However, another study noted that oxidative stress and the 
accumulation of advanced glycation end-products (AGEs) appears to promote 
the apoptosis of retinal microvascular cells and that antioxidants or AGEs 
inhibitors might ameliorate diabetic retinopathy (Yatoh et al., 2006). 
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1.4.2 Diabetic foot 
 The burden of diabetic foot disease is set to raise in the future since the 
contributory factors, such as peripheral neuropathy and vascular disease are 
observed in more than 10% of people who are diagnosed with type 2 diabetes 
and the first year after diagnosis of diabetes is a stage of danger for foot ulcers 
and amputations. Furthermore, the prevalence of type 2 diabetes is increasing 
in the developing countries such as Africa, Asia and South America (Wild et al., 
2004). Peripheral neuropathy can cause symmetric sensory failure in the feet 
and legs, ensuing in the loss of protective sensation and the combination with 
vascular injury (diminished blood flow) and infection can lead to development of 
the diabetic foot. Neuronal and vascular complications can cause small lesion 
ulcers to develop on the foot from dry skin. These may go unseen by the 
patient (due to damage in sensory nerve function) until severe infection or 
gangrene becomes recognized. Patients with diabetes must be evaluated for 
risk of developing foot lesions (ADA, 1998).  
 
Diabetic patients with sensory loss or vascular disease possibly with 
structural, skin or nail deformities are at high risk of developing foot ulcers and 
should be seen at regular intervals by a qualified professional in order to control 
diabetic foot problems (Ekere et al., 2005). These patients need to be taught on 
the role of the loss of sensory protection in foot injury and trained how to 
perform daily foot care. They should keep away from recurring weight-bearing 
exercise such as jogging, step exercise and extended walking. Diabetic 
patients who are not at high risk should be educated to understand basic 
preventative measures for foot care and have their feet inspected routinely. 
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Basic preventative measures include foot hygiene, well-fitted footwear, daily 
inspection of feet, avoidance of foot trauma and seeking professional help if 
problem occurs such as avoiding self-care of ingrown toenails, corns or athlete 
foot (Knowels et al., 1997). Those who develop new swelling, redness, 
discolourations, pain or ulceration of their feet should be referred urgently to a 
multidisciplinary foot care service (www.nice.org.uk, 2005).  
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1.4.3 Diabetic Neuropathy 
Diabetic neuropathies are a family of nerve disorders caused by 
diabetes. Diabetic neuropathies are among the most common of all the long-
term complications of diabetes affecting up to 50% of patients (Dyck et al., 
1993). People with diabetes face the risk of possible damage to nerves 
throughout the body. Neuropathies lead to numbness and sometimes pain and 
weakness in the hands, arms, feet and legs (Macleod, 1997). Problems may 
occur in every organ system, the digestive tract, heart and as well as sex 
organs. People with diabetes can experience nerve problems at any time, but 
the duration of diabetes, probably leads to high risk.  An estimated 50% of 
those with diabetes have some form of neuropathy, but not all with neuropathy 
have symptoms. The highest rates of neuropathy are among people who have 
diabetes for at least 25 years.  
 
Diabetic neuropathy is also more frequent in people who have had 
problems controlling their blood glucose levels, in those with high levels of 
blood lipids and blood pressure, in overweight people, and in people over the 
age of 40. The most common type is peripheral neuropathy, also called distal 
symmetric neuropathy, which affects the arms and legs (Abbott et al., 1998).  
 
The causes are possibly different for different varieties of diabetic 
neuropathy. Researchers are studying the effect of glucose on nerves to find 
out exactly how prolonged exposure to high glucose causes neuropathy (Oyibo 
et al., 2002). Nerve damage is due to metabolic circumstances, such as high 
blood glucose, long duration of diabetes, possibly low levels of insulin and 
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abnormal blood lipid levels (Boulton et al., 2005). Other factors that contribute 
to diabetic neuropathy such as neurovascular factors which damage the blood 
vessels that carry oxygen and nutrients to the nerves, autoimmune factors that 
cause inflammation in nerves, mechanical injury to nerves, such as carpal 
tunnel syndrome, inherited traits that increase susceptibility to nerve disease 
and lifestyle factors such as smoking or alcohol use. 
 
Symptoms depend on the type of neuropathy and which nerves are 
affected. Some people have no symptoms at all. For others, numbness, 
tingling, or pain in the feet is often the first sign (Oyibo et al., 2002). A person 
can experience both pain and numbness. Often, symptoms are minor at first, 
and since most nerve damage occurs over several years, mild cases may go 
unnoticed for a long time. Symptoms may involve the sensory or motor nervous 
system, as well as the involuntary (autonomic) nervous system (Vinik et al., 
2003). 
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1.4.4 Diabetic Nephropathy 
Diabetic nephropathy is caused by damage to the kidney and is the 
single leading cause to end-stage renal disease (ESRD). It is a major cause of 
mortality in diabetic patients (ADA; 1998d; 2002a). Mortality rate from 
cardiovascular disease in people with diabetes who also had nephropathy are 
up to eight times higher than in people who do not have diabetic nephropathy. 
The incidence of nephropathy in type 2 diabetic patients varies with ethnic 
origin and ranges from 25% (Europeans) to 50% (African-Caribbean, South 
Asian and Japanese). The higher incidence in African-Caribbean and South 
Asian may be due to higher frequency of arterial hypertension and a younger 
age of onset of type 2 diabetes, respectively (Viberti, 1997).  
 
Diabetic nephropathy is defined as the presence of albuminuria from 
urine test. The clinical symptoms of diabetic nephropathy develop over several 
years. Early changes in renal function include glomerular hyperfiltration, 
increased renal blood flow and hypertrophy of the kidney. Microalbuminuria 
(albumin excretion rate 30-299 mg/24hours) is the first sign of diabetic 
nephropathy. Macroalbuminuria develops in 20-40% of type 2 diabetic patients 
with microalbuminuria over a period of 10-15 years. In these patients with 
macroalbuminuria, the glomerular filtration rate falls over a period of several 
years. Once overt nephropathy (macroalbuminuria) occurs, ESRD develops 
only in 20% of type 2 diabetic patients after 20 years (ADA, 2002a). Patients 
with macroalbuminuria (clinical nephropathy) have an albumin excretion rate 
>300 mg/24hours. There are three methods for microalbuminuria screening. 
The first method is measurement of albumin to creatinine ratio in a random spot 
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urine collection. Secondly, 24-hr urine collection with creatinine, allowing the 
simultaneous measurement of creatinine clearance and finally timed urine 
collection (Table 1.3).  
 
Table 1.3 Definitions of abnormalities in albumin excretion 
 
Category 24-hr collection 
(mg/24 hr) 
Timed collection 
(µg/min) 
Spot collection 
(µg/mg creatinine)
Normal <30 <20 <30 
 
 
 
Microalbuminuria 30-299 20-199 30-299 
 
 
 
Clinical 
albuminuria 
≥300 ≥200 ≥300 
 
Because of variability in urinary albumin excretion, two of three specimens 
collected within a 3 to 6 month period should be abnormal before considering a 
patient to have crossed one of diagnostic threshold. Exercise within 24 hr, 
infection, fever, congestive heart failure, marked hyperglycemia, marked 
hypertension, pyuria and hematuria may elevate urinary albumin excretion over 
baseline values (ADA, 2002a). 
 
 
 
In people with diabetes who already have nephropathy, tight blood 
glucose control and tight control of high blood pressure can significantly reduce 
the decline in renal function. 
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1.4.5 Diabetic Retinopathy 
Estimates of the incidence of diabetic retinopathy range widely and are 
increasing around the world. About 135 million individuals are diagnosed with 
diabetic retinopathy. Data from ADA demonstrated that in America diabetic 
retinopathy affects over 18.2 million people or 6.3% of the total population. 
Retinopathy results from damage to the capillaries supplying the retina and is a 
major cause of blindness in people with diabetes (Donald et al., 2004; ADA, 
1998a; 2001; 2002b). The risk of developing retinopathy increases with 
duration of diabetes (ADA, 1998a; 2001; 2002b) and poor blood glucose control 
(Donald et al., 2004). Other risk factors for retinopathy include hypertension, 
dyslipidaemia (ADA, 1998a; 2001; 2002b) and pregnancy 
(www.doh.gov.uk/nsf/diabetes, 2002). The main types of retinopathy 
associated with visual loss are proliferative retinopathy in which new blood 
vessels develop, thus leading to haemorrhage and scarring. Mean while, 
maculopathy occurs where there is capillary blood vessel leakage into the 
retina. If untreated, 6-9% of people with proliferative retinopathy become blind 
each year and 10% of people with maculopathy develop moderate visual loss 
each year.  
 
A recent study (Donald et al., 2004) proposed that there is a link 
between hyperglycemia and biochemical pathway leading to microvascular 
complications. This includes activation of protein kinase C (PKC), polyol 
pathway, formation of AGEs and oxidative stress. These processes are thought 
to modulate the disease process through effects on cellular metabolism, 
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signaling and growth factors. In addition, it is important to keep the blood 
glucose in normal range in order to prevent diabetic retinopathy. 
 
1.5 Apoptosis 
 
1.5.1   Definition and Causes 
 
 Apoptosis is energy-dependent, natural, genetically controlled process 
by which the organism eliminates unnecessary single cells (Mallat & Tedgui, 
2000). The term apoptosis had been coined in order to explain the 
morphological processes principal to controlled cellular self-destruction and 
was first discovered in a publication by Kerr, Wyllie and Currie (Kerr, 1972).  
Apoptosis is of Greek origin, meaning “falling off or dropping off”, in analogy to 
leaves falling off trees or petals dropping off flowers. This analogy emphasizes 
that the death of living matter is an essential and compulsory part of the life 
cycle of any organism. 
 
 The apoptotic form of cell death is an active and defined process which 
plays an important role in the development of multicellular organisms and in the 
regulation and preservation of the cell populations in tissues in physiological 
and pathological conditions. It should be stressed that apoptosis is a well-
defined and possibly the most common form of programmed cell death, but that 
other, non apoptotic types of cell death also might be of biological significance 
(Leist, 2001).  
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Apoptosis is an orderly and tightly controlled series of events in gene 
expression and protein activities. It plays a major role in normal growth and 
differentiation of organ systems and appears to be involved in a variety of 
human disorders (Li et al., 2004). 
 
Apoptosis is associated with the onset and development of diabetes. It 
has been demonstrated that free fatty acids (Lupi et al., 2002), protooncogene 
(c-Myc) (Laybutt et al., 2002), oxidative stress (Gorogawa et al., 2002), high 
glucose (O’Brien et al., 1997), and Fas (Savinov et al., 2003) induce apoptosis 
of pancreatic β-cells, leading to the development of diabetes. Furthermore, high 
glucose, AGEs, glycated LDL and oxidative stress have been revealed to 
induce cell apoptosis in retina (Mizutani et al., 1996), kidney, neuron, 
myocardial cells and vascular endothelial cells, which is related to the 
acceleration of diabetic complications and atherosclerosis (Podesta et al., 
2000; Mohr et  al., 2002 & Artwohl et  al., 2003).  
 
There are two gene families that are mostly important in the control of 
apoptosis; the genes encoding the interleukin-1–converting enzyme (ICE) 
family of cysteine proteases (caspases) and those related to the proto-
oncogene Bcl-2. Both of these families are homologous to cell death genes in 
Caenorhabditis elegans (C. elegans) (Hale et al., 1996). Proteolytic activity is 
implicated in many apoptotic systems, the ICE family being of special 
importance, since it seems to be central in Fas-mediated and tumor necrosis 
factor (TNF)-induced apoptosis.  
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Proteolysis is probably a common incident in the apoptotic process, with 
different proteases involved and several proteins having been shown to be the 
subject of proteolytic activity.  
 
New evidence suggests that Bcl-2 protein has two different functions: 1) 
as an ion channel protein and 2) as an adaptor/docking protein through its 
binding to several other proteins which are important in modulating the 
apoptosis. However, the precise way in which these proteins modulate 
apoptosis is unclear and conflicting theories have been proposed (Hale et al., 
1996). Further, the gene product of Bcl-2 does not prevent apoptosis under all 
conditions (e.g., does not protect target cells from apoptosis induced by 
cytotoxic T cells [Vaux et al., 1992]). Finally, genes involved in cell 
differentiation and proliferation are also important in modulating the apoptotic 
process (e.g., the c-Myc, the p53, and the apoptosis suppressor gene A20). 
Both c-Myc and p53 are implicated in the induction of apoptosis under certain 
conditions, whereas A20 is a cytokine-induced primary response gene involved 
in the inhibition of the apoptotic process (Hale et al., 1996). 
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1.5.2 Morphology 
 
 Apoptotic cells can be recognized by morphological changes which are 
the cell shrinks, shows deformation and looses contact with its neighbouring 
cells (Figure 1.1). Its chromatin condenses and marginates at the nuclear 
membrane, the plasma membrane is blebbing or budding, and finally the cell is 
fragmented into compact membrane-enclosed structures, called 'apoptotic 
bodies' which contain cytosol, the condensed chromatin, and organelles. The 
apoptotic bodies are engulfed by macrophages and thus are removed from the 
tissue without causing an inflammatory response (Kerr et al., 1972). 
 
Those morphological changes are a consequence of characteristic 
molecular and biochemical events occurring in an apoptotic cell, most 
particularly the activation of proteolytic enzymes which eventually mediate the 
cleavage of DNA into oligonucleosomal fragments as well as the cleavage of a 
multitude of specific protein substrates which usually determine the integrity 
and shape of the cytoplasm or organelles (Saraste, 2000). Apoptosis is in 
contrast to the necrotic mode of cell death in which case the cells suffer a major 
assault, resulting in a loss of membrane integrity, swelling and disruption of the 
cells. During necrosis, the cellular contents are released uncontrolled into the 
cell's environment which results in damage of surrounding cells and a strong 
inflammatory response in the corresponding tissue (Leist, 2001). 
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Figure 1.1 Hallmarks of the apoptotic and necrotic cell death process. 
 
Apoptosis includes cellular shrinking, chromatin condensation and margination at 
the nuclear periphery with the eventual formation of membrane-bound apoptotic 
bodies that contain organelles, cytosol and nuclear fragments and are 
phagocytosed without triggering inflammatory processes. The necrotic cell 
swells, becomes leaky and finally is disrupted and releases its contents into the 
surrounding tissue resulting in inflammation (taken from Van Cruchten, 2002).  
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